Genelux Corporation (GNLX)
GNLX Stock Price Chart
Explore Genelux Corporation interactive price chart. Choose custom timeframes to analyze GNLX price movements and trends.
GNLX Company Profile
Discover essential business fundamentals and corporate details for Genelux Corporation (GNLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2023
Employees
24.00
Website
https://www.genelux.comCEO
Thomas Zindrick
Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Financial Timeline
Browse a chronological timeline of Genelux Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.23.
Earnings released on 7 Aug 2025
EPS came in at -$0.20 surpassing the estimated -$0.22 by +9.09%.
Earnings released on 6 May 2025
EPS came in at -$0.21 surpassing the estimated -$0.24 by +12.50%.
Earnings released on 28 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $452.00K .
Earnings released on 14 Nov 2024
EPS came in at -$0.19 matching the estimated -$0.19.
Earnings released on 14 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%.
Earnings released on 9 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%, while revenue for the quarter reached $8.00K .
Earnings released on 29 Mar 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $1.46M .
Earnings released on 14 Nov 2023
EPS came in at -$0.20 falling short of the estimated -$0.12 by -66.67%.
Earnings released on 14 Aug 2023
EPS came in at -$0.23 falling short of the estimated -$0.15 by -53.33%.
Earnings released on 15 May 2023
EPS came in at -$0.53 falling short of the estimated -$0.16 by -230.89%, while revenue for the quarter reached $170.00K , meeting expectations.
Earnings released on 26 Jan 2023
EPS came in at -$0.13 surpassing the estimated -$0.17 by +22.12%, while revenue for the quarter reached $68.00K .
Earnings released on 30 Sept 2022
EPS came in at $0.16 , while revenue for the quarter reached $11.00M .
Earnings released on 30 Jun 2022
EPS came in at -$0.13 .
Earnings released on 31 Mar 2022
EPS came in at -$0.13 .
Earnings released on 31 Dec 2021
EPS came in at -$0.12 .
Earnings released on 30 Sept 2021
EPS came in at -$0.14 .
Earnings released on 30 Jun 2021
EPS came in at -$0.31 .
Earnings released on 31 Mar 2021
EPS came in at -$0.10 .
Earnings released on 31 Dec 2020
EPS came in at -$0.14 .
Earnings released on 30 Sept 2020
EPS came in at -$0.14 .
GNLX Stock Performance
Access detailed GNLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.